TRA-1-60
Our lead cancer target, TRA-1-60 is highly present on normal human embryonic stem cells during embryogenesis. This large carbohydrate molecule disappears when embryonic stem cells differentiate into somatic cells.
Since 2012, CureMeta has generated compelling preclinical research data showing TRA-1-60 is present on the cell surface of cancer cells in aggressive and metastatic tumors. Nine independent research groups around the world have published scientific studies confirming TRA-1-60 as an important tumor marker in many kinds of cancer.
To the right is a picture of gastric cancer stained for TRA-1-60 (brown color indicates the presence of the molecule) as well as a graph showing TRA-1-60 staining pattern in 28 of 34 cases of metastatic gastric cancer, and no staining in normal gastric specimens without cancer.
Lead Drug CM-09
Bstrongximab is a human/mouse chimeric IgG1 antibody with high specificity and high affinity to TRA-1-60. Our CM-09 drug is an antibody-drug-conjugate with the toxin Mono-Methyl Auristatin E attached to the Bstrongximab antibody. CM-09 is internalized into the cancer cell where the toxin is released causing cell death. CM-09 binds only to cancer cells and not normal cells, thus providing a highly specific targeted mechanism of action. Our preclinical research shows CM-09 to be a first-in-class cancer drug with high potency and killing efficacy for a number of difficult-to-treat cancers.